| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial.
|
J Urol
|
2010
|
2.68
|
|
2
|
OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
|
Eur Urol
|
2013
|
2.59
|
|
3
|
Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
|
Eur Urol
|
2011
|
2.37
|
|
4
|
Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity.
|
J Urol
|
2012
|
2.29
|
|
5
|
A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia.
|
Eur Urol
|
2012
|
1.61
|
|
6
|
Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database.
|
Neurourol Urodyn
|
2010
|
1.55
|
|
7
|
OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial.
|
J Urol
|
2012
|
1.46
|
|
8
|
Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder.
|
Eur Urol
|
2007
|
1.40
|
|
9
|
Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome.
|
J Urol
|
2007
|
1.27
|
|
10
|
Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder.
|
Neurourol Urodyn
|
2011
|
1.06
|
|
11
|
OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity [corrected] regardless of concomitant anticholinergic use or neurologic etiology.
|
Adv Ther
|
2013
|
1.06
|
|
12
|
Long-term efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: an interim analysis.
|
Urology
|
2013
|
0.93
|
|
13
|
OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity.
|
Neurourol Urodyn
|
2013
|
0.87
|